Replication ability in vitro and in vivo of equine infectious anemia virus avirulent Japanese strain.

The research article investigates the replication abilities of an attenuated strain of equine infectious anemia virus (EIAV), known as V26, both in vitro (in the laboratory) and in vivo (in the body). The strain V26 is known to produce neutralizing antibodies against EIAV without causing detectable viremia in inoculated horses. The study centered on the large insertion within the long-terminal repeat (LTR) sequences of V26, its promoter activity, and the virus replication rate compared to the virulent strain V70.

Research Methodology

• The scientists started by comparing the long-terminal repeat (LTR) sequences between the V26 and the V70 strains. The LTR is a crucial part of a virus that helps control the replication of the virus. This comparison revealed a significant insertion within the LTR U3 hypervariable region of V26.
• They experimented the in vitro replication rate of V26 by measuring its promoter activity, which is the process that initiates transcription of a gene. Compared to V70, V26 had a much higher promoter activity, indicating a higher replication rate.
• The researchers also studied the virus’s in vivo replication ability. They used a Polymerase Chain Reaction (PCR) to detect the V26-specific LTR sequence in sequential samples of plasma or peripheral blood mononuclear cells collected from horses inoculated with V26.

Findings of the Study

• It was found that V26 had a higher replication rate than V70 in vitro.
• In contrast to the in vitro experiment, the researchers could not detect the V26-specific LTR sequence in any body samples collected from the inoculated horses, suggesting that V26’s replication in vivo was extremely low.
• Despite the low replication ability in vivo, all inoculated horses exhibited antibody responses to EIAV.
• When one inoculated horse was subsequently exposed to V70, it was found to be PCR positive for EIAV, suggesting that the inoculation with V26 did not confer enough immunity to prevent subsequent infection with V70.

Conclusion

• The study concludes that the LTR mutation in EIAV, which occurs during the serial passage in the laboratory, impacts EIAV’s replication ability both in vitro and in vivo. This could have implications for vaccine development strategies against EIAV, especially regarding the use of the V26 strain.